0.05Open0.05Pre Close0 Volume232 Open Interest2.50Strike Price0.00Turnover300.65%IV176.27%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1789Delta0.3708Gamma18.47Leverage Ratio-0.0039Theta0.0001Rho3.30Eff Leverage0.0006Vega
Lyell Immunopharma Stock Discussion
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphoma
Presenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024...
05/11/2024 - 22:30
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, ...
Dow Jones· just
$Lyell Immunopharma (LYEL.US)$
$Edible Garden (EDBL.US)$ 👍
No comment yet